Clinical trials: T-Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
RadiothErapy priMIng for CAR-T
The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
- Trial name
- REMIT (NCT04726787)
- Testing
- Bridging Radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University College, London
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
- Conditions
- Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
- Trial name
- NCT06151106
- Testing
- Chidamide combined with Duvillisib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
B-Cell Acute Lymphoblastic Leukemia, Adult
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults.
- Trial name
- NCT07277504
- Testing
- CD19 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The General Hospital of Western Theater Command
Mycoses, Sezary Syndrome
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of…
- Conditions
- Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure
- Trial name
- NCT00896493
- Testing
- anti-thymocyte globulin, cyclosporine, Lymphoid radiation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with…
- Trial name
- NCT04213209
- Testing
- Brentuximab Vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 95 people
- Sponsor
- Takeda
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL)
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
The goal of this clinical trial is to evaluate whether the drug Loncastuximab Tesirine can treat patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) who have not…
- Conditions
- Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
- Trial name
- LORELY (NCT06918912)
- Testing
- Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
- Where
- 7 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Clinico Humanitas
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL)
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be…
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04450069
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Calibr, a division of Scripps Research
Lymphoma, Non-melanomatous Skin Cancer
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Conditions
- Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition
- Trial name
- NCT00103246
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Peripheral T Cell Lymphoma
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
- Trial name
- NCT04470141
- Testing
- SHC014748M treatment
- Volunteers
- 130 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Natural Killer T-cell Lymphoma
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural…
- Trial name
- JACKPOT50 (NCT06733051)
- Testing
- Golidocitinib, Benmelstobart
- Where
- 2 sites in China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03035331
- Testing
- Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
T-lymphoblastic Lymphoma, NK/T Cell Lymphoma
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia.
- Conditions
- T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT04004637
- Testing
- CD7 CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment.
- Conditions
- T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma
- Trial name
- NCT02588651
- Testing
- Brentuximab vedotin
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Deepa Jagadeesh
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Cutaneous T Cell Lymphoma
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
This is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT03235869
- Testing
- Durvalumab, Radiation Therapy
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Immune Checkpoint Inhibitor, Chemotherapy Effect
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
- Conditions
- Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity
- Trial name
- NCT04414969
- Testing
- Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Hunan Cancer Hospital
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
NK/T-Cell Lymphoma
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
- Trial name
- NCT04490590
- Testing
- Chidamide+ Etoposide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mingzhi Zhang
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.